​​A Phase 1, Open-Label, Multiple-Part Trial to Evaluate the Drug-Drug Interaction Potential of PRAX-628 in Healthy Participants​

2024-514426-23-01 Protocol PRAX-628-102 Human pharmacology (Phase I) - Other Ended

Start 28 Aug 2024 · End 24 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol PRAX-628-102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 62
Countries 1
Sites 1

Epilepsy

Key facts

Sponsor
Praxis Precision Medicines Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
28 Aug 2024 → 24 Feb 2025
Decision date (initial)
2024-08-21
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Epilepsy

VersionLevelCodeTermSystem organ class
21.1 LLT 10065337 Focal epilepsy 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Praxis Precision Medicines Inc.

Sponsor organisation
Praxis Precision Medicines Inc.
Address
99 High Street Floor 30th
City
Boston
Postcode
02110-2345
Country
United States

Scientific contact point

Organisation
Praxis Precision Medicines Inc.
Contact name
William Motel

Public contact point

Organisation
Praxis Precision Medicines Inc.
Contact name
William Motel

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 62 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-08-28 2024-08-28 2025-01-17

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-04 Netherlands Acceptable
2024-08-21
2024-08-21
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-13 Netherlands Acceptable
2024-12-06
2024-12-06